Services // Clinical Research

QUICK LOOK:

For all Oncology Trials
Contact Michelle Mackenzie, RN, OCN, CRC at 973-436-1755 or mmackenzie@smgnj.com

For all other Studies
Contact Kelly Ritter, LPN, CCRC at 908-721-5673 or kritter@smgnj.com

Service Type Name Title
Cancer Services Hematologic Lymphoma—Mantle Cell Lymphoma R/R, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma NCT02793583
Cancer Services Hematologic Acute Myeloid Leukemia, Phase 2/3 A Phase 2/3 Multicenter, Open-label, 3 arm, 2 stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy NCT02752035
Cancer Services Breast Adjuvant Radiation, Phase 2 A Phase II Study of Hyporfactionated Partial Breast Irradiation in Women with Early Stage Breast Cancer NCT03077817
Cancer Services Breast Early Stage HR+, HER2-, Early Stage Invasive Breast Cancer, Phase 3 monarchE: Randomized Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy vs Standard Adjuvant Endocrine Therapy Alone in patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer NCT03155997
Cancer Services Hematologic Follicular Lymphoma R/R, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab and TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma NCT02793583
Cancer Services Hematologic Follicular Lymphoma R/R, Phase 1 An Open-Label, Dose Finding, and Cohort Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination with Bendamustine and Obinutuzumab in Subjects with Relapsed or Refractory Follicular Lymphoma (CITADEL-102) NCT03039114
Cancer Services Hematologic Follicular Lymphoma R/R, Phase 2 An International Phase 2, Open Label, Randomized Study of BGB-3111 Comgined with Obinutuzumab Compared with Obinutuzumab Monotherapy in Relapsed/Refractory Follicular Lymphoma NCT03332017
Cancer Services Hematologic Follicular Lymphoma Treatment Naïve, Phase 3 A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyronise Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma NCT02947347
Cancer Services Hematologic Myelofibrosis, Phase 2 A Phase 2 Study of the Safety, Tolerability and Efficacy of INCB050465 in Combination with Ruxoltinib in Subjects with Myelofibrosis NCT02718300
Cancer Services Hematologic Essential Thrombocytopenia, Phase 2 A Double-blind, Double-dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib versus Anagrelide in subjects with Essential Thrombocytopena who are Resistant to or intolerant of Hydroxyurea NCT03123588
Cancer Services Hematologic ET/MF, Phase None Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-risk Essential Thrombocytopenia (ET) or ET Patients Receiving ET-Directed Therapy NCT02953704
Cancer Services Hematologic Hodgkin Disease Observational, Phase None Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices NCT02856646
Cancer Services Hematologic Lymphoma—Mantle Cell Lymphoma Treatment Naive, Phase 3 A Phase 3, Randomized, Double Blind, Placebo-controlled, Multi-center, Study of Bendamustine and Rituximab (BR) Alone versus in Combination with Acalabrutinib in Subjects with Previously Untreated Mantle Cell Lymphoma NCT02972840
Cancer Services Hematologic SLL R/R ≥ 2 prior lines of systemic therapy, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma NCT02793583
Cancer Services Hematologic Chronic Lymphocytic Leukemia (CLL): R/R CLL/SLL or B-Cell NHL, Phase 1/2A A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)
Cancer Services Hematologic Chronic Lymphocytic Leukemia (CLL): CLL/SLL Untreated, Phase 3 An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphoctytic Lymphoma NCT03336333
Cancer Services Gastric Colorectal: Previously treated Metastatic Colorectal Cancer, Phase 3 A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) with or without Bevacizumab in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)
Cancer Services Hematologic Diffuse Large B Cell Lymphoma (DLBCL) Relapsed/Refractory: Lymphoma – DLBCL R/R, Phase 2/3 A Phase II/III, Randomized, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL_ Who are Not Eligible for High Dose Chemotherapy and Autologous Stem Cell Transplantation (B-MIND) NCT02763319
Cancer Services Hematologic Diffuse Large B Cell Lymphoma (DLBCL) Relapsed/Refractory: Lymphoma – DLBCL R/R, Phase 1B/2 A Multicenter Open-label Phase 1b/2 Study of the Bruton’s Tyrosine Kinase Inhibitor, Ibruitinib, in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B Cell Lymphoma NCT02077166
Cancer Services Gastric Metastatic Pancreatic Cancer, 2nd Line, Phase 3 A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX alone as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer that has Progresse4d During or Following a First Line Gemcitabine Containing Regimen NCT02923921
Cancer Services Lung Non-Small Cell Lung (NSCLC): Lung - Adjuvant, Phase 3 A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PD-L1−SELECTED PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER  NCT02486718
Cancer Services Lung Small-Cell Lung (SCLC): Small-Cell Lung Cancer-2nd line, Phase 3 Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients with Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum containing Line (ATLANTIS Trial). NCT02566993
Cancer Services Lung Non Small-Cell Lung (SCLC): Lung EGFR+, Phase 3 A Phase III, Double-blind, Randomized, Placebo Controlled, Multi Centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA NonSmall Cell Lung Carcinoma Following Complete Tumor Resection with or without Adjuvant Chemotherapy (ADAURA) NCT02511106
Cancer Services Breast Metastatic: Triple Negative 1st Line Metastatic, Phase 1B/2 Single Arem, Open Label Phase 1b/2 Study of SGN-LV1A in Combination with Pembrolizumab for the First Line Treatment of Patients with Unresectable Locally-Advanced or Metastatic Triple Negative Breast Cancer NCT03310957
Cancer Services Hematologic Chronic Lymphocytic Leukemia (CLL): R/R CLL/SLL, Phase 2 A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Chronic Lymphocytic Lymphoma Previously Treated wutg a Bruton’s Tyrosine Kinase Inhibitor
Cancer Services Hematologic DLBCL – Untreated, Phase 3 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Vs. R-CHOP in Treatment-Naïve Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™ NCT03263026
Cancer Services Lung Non-Small Cell Lung (NSCLC): Advanced NSCLC, Phase 2 Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination with Pembrolizumab in Patients with Non-Small Cell Lung Cancer NCT03309842
Cancer Services Lung Non-Small Cell Lung (NSCLC): Lung Screening, Phase None Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer NCT03457415
Cancer Services Gynecologic Endometroid Ovarian, Fallopian Tube, or Primary, Phase 2 Non-Randomized, Open Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum Sensitive, Relapsed, High-grade Serious or High-grade Endometroid Ovarian, Fallopian Tube or Primary Peritoneal Cancer that have Received at Least One Prior Line of Chemotherapy
Cancer Services Hematologic Lymphoma-Marginal Zone R/R, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma NCT02793583
Cancer Services Hematologic Diffuse Large B Cell Lymphoma (DLBCL) Relapsed/Refractory: Lymphoma DLBCL- Previously Treated, Phase 2B A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma
Cancer Services Gastric Cholangiocarcinoma: Relapsed Cholangiocarcinoma with FGFR translocation, Phase 2 A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations who failed Previous Therapies NCT0292437
NAVIGATION WE ARE HERE TO HELP YOU! STAY CONNECTED Like Tweet Share Follow Instagram